SUNPHARMA

Pharma stocks witnessed a sharp decline on Friday after US President Donald Trump hinted at upcoming tariffs on pharmaceutical imports. The Nifty Pharma index tumbled over 6%, with major Indian pharma companies taking a hit. Despite this setback, stock market experts believe the sector remains attractive for long-term investors. With India supplying a significant portion of US generic drugs, the industry’s resilience and growth prospects continue to offer opportunities.